[Anti-citrulline antibodies and treatment with anti-tumor-necrosis-factor-alpha and rituximab].
Callejas Rubio
José Luis
JL
Fernández Roldán
Concepción
C
Ríos Fernández
Raquel
R
Ortego Centeno
Norberto
N
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D001324:Autoantigens / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D000069285:Infliximab; D010456:Peptides, Cyclic / Q000276:immunology*; D011237:Predictive Value of Tests; D000069283:Rituximab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001324:Autoantigens; D010456:Peptides, Cyclic; D014409:Tumor Necrosis Factor-alpha; C487763:cyclic citrullinated peptide; D000069283:Rituximab; D000069285:Infliximab